Clinical Trials on HPV - Anogenital Human Papilloma Virus Infection

Total 11757 results

ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769/KALETRA Drug-drug Interaction Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single and Repeated Dose Escalation Study of GSK2838232

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) (ASSURE)

Infection, Human Immunodeficiency Virus

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

Infection, Human Immunodeficiency Virus I
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Dolutegravir Renal Impairment Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
RXi Pharmaceuticals, Corp.

Unknown

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Plantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual Warts

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

Infection, Human Immunodeficiency Virus | Fracture
Henan Provincial People's Hospital
Merck Sharp & Dohme LLC

Unknown

Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection

HIV Infections | Liver Toxicity | Hepatitis Co-infection
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO) (PROMO)

HCV Infections | Gastric Acid-related Disorders

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults

Human Papillomavirus Infection | Human Papillomavirus-Related Carcinoma

United States
University of Washington

Active, not recruiting

Immunogenicity of Fractional Dose of the HPV Vaccines

HPV Infection | HPV Vaccine

United States
Rush University Medical Center
Merck Sharp & Dohme LLC; University of North Carolina, Chapel Hill; Ruth M. Rothstein...

Completed

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

Fibrosis | HIV Infection | Inflammation | Hepatitis C Infection

United States
Memorial University of Newfoundland

Recruiting

APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies

HIV Infections | HCV Infection | Syphilis Infection

Canada
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; Maryland Department of Public Safety and Correctional...

Withdrawn

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) (ECLIPSE)

HCV Infection

United States
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

HCV Infection

United States, Puerto Rico
University Hospital, Strasbourg, France

Unknown

Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.

HCV Infection

France
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (SALIF)

Human Immunodeficiency Virus-type 1 Infection

South Africa, Kenya, Thailand, Uganda, Cameroon, Senegal
ViiV Healthcare
GlaxoSmithKline

Completed

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Infection, Human Immunodeficiency Virus I
Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
Université Catholique de Louvain
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Infection, Human Immunodeficiency Virus

Argentina
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Infection, Human Immunodeficiency Virus

United States, France, Germany, Canada, Spain, United Kingdom, Mexico, Italy, Argentina, Chile, South Africa, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Fosamprenavir Versus Other Protease Inhibitors

Infection, Human Immunodeficiency Virus I

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Mills Clinical Research
ViiV Healthcare

Unknown

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC (STRUCTR)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Relative Bioavailability Study

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

No longer available

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Infection, Human Immunodeficiency Virus

Belgium, Russian Federation, Italy, South Africa, Argentina, Switzerland, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Infection, Human Immunodeficiency Virus

United States, France, Spain, Canada, Italy

Clinical Trials on HPV - Anogenital Human Papilloma Virus Infection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations